| Q92702921 | A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease |
| Q38896793 | Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance |
| Q52876323 | C3 Glomerulopathy. |
| Q49691328 | C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab. |
| Q39207807 | C3 glomerulopathy |
| Q64041044 | C3 glomerulopathy - understanding a rare complement-driven renal disease |
| Q88578407 | C3 glomerulopathy associated with monoclonal Ig is a distinct subtype |
| Q26829790 | Complement cascade and kidney transplantation: The rediscovery of an ancient enemy |
| Q35567841 | Complement involvement in kidney diseases: From physiopathology to therapeutical targeting |
| Q37522557 | Complement related kidney diseases: Recurrence after transplantation |
| Q58120548 | Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseases |
| Q38843499 | Current status of pediatric renal transplant pathology |
| Q40751722 | De novo C3 glomerulonephritis in a renal allograft |
| Q47172094 | De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases? |
| Q55450113 | Eculizumab as salvage therapy for recurrent monoclonal gammopathy-induced C3 glomerulopathy in a kidney allograft. |
| Q42392710 | Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis |
| Q33425245 | High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies |
| Q38275117 | Histopathology of MPGN and C3 glomerulopathies |
| Q38549182 | Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. |
| Q100697445 | Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors |
| Q86932651 | Likely Recurrence of C3 Glomerulonephritis in Kidney Transplantation: An Entity to Bear in Mind: Case Report |
| Q35891170 | Membranoproliferative glomerulonephritis recurrence after kidney transplantation: using the new classification. |
| Q48257502 | Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series. |
| Q92600851 | Pathophysiology and management of monoclonal gammopathy of renal significance |
| Q38445275 | Primary disease recurrence—effects on paediatric renal transplantation outcomes |
| Q38752824 | Primary glomerulonephritides |
| Q26741542 | Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN |
| Q47193282 | Recurrence of primary glomerulonephritis: Review of the current evidence |
| Q93047764 | Recurrent and de novo Glomerulonephritis After Kidney Transplantation |
| Q38749694 | Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies |
| Q38587928 | The emerging role of complement inhibitors in transplantation |
| Q97545713 | The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis |
| Q47720351 | The role of complement inhibition in kidney transplantation |
| Q48252388 | Treating C3 glomerulopathy with eculizumab. |
| Q38880897 | Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies |
| Q40744602 | Update on C3 glomerulopathy. |
Search more.